Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H20N2O3 |
Molecular Weight | 264.3202 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
InChI
InChIKey=WAEXFXRVDQXREF-UHFFFAOYSA-N
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
Molecular Formula | C14H20N2O3 |
Molecular Weight | 264.3202 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB02546Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB02546
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. Vorinostat is used for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat is marketed under the name Zolinza by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22090453
Curator's Comment: Vorinostat was shown to cross the blood-brain barrier in a mouse model of Huntington's disease. It inhibited the growth of GL26 GBM cells implanted into the brains of mice. Vorinostat treatment induced accumulation of acetylated histones H2B, H3, and H4 in patients with recurrent GBM.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2366922 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26199860 |
0.12 µM [IC50] | ||
Target ID: CHEMBL1075544 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
0.13 µM [IC50] | ||
Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
0.15 µM [IC50] | ||
Target ID: CHEMBL1937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
0.28 µM [IC50] | ||
Target ID: CHEMBL3192 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
1.68 µM [IC50] | ||
Target ID: CHEMBL1829 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19410459 |
57.0 nM [IC50] | ||
Target ID: CHEMBL1865 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25734520 |
1.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Zolinza Approved UseTreatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Launch Date2006 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.2 μM |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
0.83 uM Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
1.17 uM Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.5 μM × h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
4.59 uM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
5.59 uM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
1.94 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
2.3 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
29% |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 2 times / day multiple, oral Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 63 years (range: 38 - 74 years) n = 5 Health Status: unhealthy Condition: advanced multiple myeloma Age Group: 63 years (range: 38 - 74 years) Population Size: 5 Sources: |
DLT: Fatigue... Dose limiting toxicities: Fatigue (grade 3, 1 patient) Sources: |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Disc. AE: Thrombocytopenia, Anemia... Other AEs: Hypotension, Sepsis... AEs leading to discontinuation/dose reduction: Thrombocytopenia (grade 3-4, 8%) Other AEs:Anemia (grade 3-4, 17%) Deep vein thrombosis (grade 3-4, 25%) Pyrexia (grade 3-4, 25%) Pulmonary embolism (grade 3-4, 17%) Hypotension (grade 3-4, 17%) Sources: Sepsis (grade 3-4, 8%) Fatigue (all grades, 27%) Diarrhea (11%) Nausea (8%) Dysgeusia (11%) Weight loss (3%) Vomiting (11%) Anorexia (3%) Blood creatinine increased (8%) Dehydration (5%) Anemia (5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Fatigue | grade 3, 1 patient DLT, Disc. AE |
250 mg 2 times / day multiple, oral Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 63 years (range: 38 - 74 years) n = 5 Health Status: unhealthy Condition: advanced multiple myeloma Age Group: 63 years (range: 38 - 74 years) Population Size: 5 Sources: |
Diarrhea | 11% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Dysgeusia | 11% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Vomiting | 11% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Anorexia | 3% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Weight loss | 3% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Anemia | 5% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Dehydration | 5% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Blood creatinine increased | 8% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Nausea | 8% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Fatigue | all grades, 27% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Hypotension | grade 3-4, 17% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Anemia | grade 3-4, 17% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Pulmonary embolism | grade 3-4, 17% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Deep vein thrombosis | grade 3-4, 25% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Pyrexia | grade 3-4, 25% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Sepsis | grade 3-4, 8% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Thrombocytopenia | grade 3-4, 8% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 31.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. | 2001 |
|
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. | 2001 Jan-Feb |
|
Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). | 2001 Nov |
|
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. | 2001 Sep 11 |
|
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. | 2002 Jan 17 |
|
One-step SFE-plus-C(18) selective extraction of low-polarity compounds, with lipid removal, from smoked fish and bovine milk. | 2002 Nov |
|
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. | 2003 Apr 15 |
|
Phosphorus-based SAHA analogues as histone deacetylase inhibitors. | 2003 Aug 21 |
|
Gateways to clinical trials. | 2003 Dec |
|
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. | 2003 Feb |
|
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. | 2003 May 15 |
|
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. | 2003 Sep 1 |
|
Suberanilohydroxamic Acid. Aton Pharma. | 2004 Jul |
|
Role of oxidative enzymatic treatments on enzymatic hydrolysis of softwood. | 2004 Jun 5 |
|
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. | 2004 Oct |
|
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. | 2004 Sep 15 |
|
High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. | 2005 |
|
Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. | 2005 Feb 24 |
|
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. | 2005 Jan |
|
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. | 2005 Mar |
|
Crystal structure of a bacterial class 2 histone deacetylase homologue. | 2005 Nov 18 |
|
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. | 2005 Oct |
|
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. | 2005 Sep |
|
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. | 2006 Jan |
|
5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. | 2006 Jan |
|
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. | 2006 Jul 1 |
|
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. | 2006 Mar |
|
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. | 2006 Mar 3 |
Patents
Sample Use Guides
400 mg orally once daily with food.
If patient is intolerant to therapy, the dose may be reduced to
300 mg orally once daily with food. If necessary, the dose may be
further reduced to 300 mg once daily with food for 5 consecutive
days each week.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23856614
Concentrations of vorinostat higher than 0.5 uM significantly inhibited the upregulated gene expression of MMP-1 and MMP-13 induced by IL-1β, whereas 0.1 uM vorinostat showed no obvious effect. Conversely, 0.5 uM vorinostat or higher concentration increased the TIMP-1 expression.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:47:37 GMT 2023
by
admin
on
Sat Dec 16 15:47:37 GMT 2023
|
Record UNII |
58IFB293JI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
177203
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
WHO-VATC |
QL01XX38
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/11/854
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
LIVERTOX |
NBK548004
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
NCI_THESAURUS |
C1946
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
NDF-RT |
N0000175588
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
FDA ORPHAN DRUG |
540116
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
WHO-ATC |
L01XX38
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
NDF-RT |
N0000175071
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
FDA ORPHAN DRUG |
174203
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
||
|
FDA ORPHAN DRUG |
169503
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL98
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
100000088823
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
4124
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
149647-78-9
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
m11502
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
7930
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
5311
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
194337
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
759852
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
58IFB293JI
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
58IFB293JI
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
C111237
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
8661
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
C1796
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
45716
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
6852
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
701852
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
748799
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
VORINOSTAT
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
RR-09
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
DTXSID6041133
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
SUB23356
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY | |||
|
DB02546
Created by
admin on Sat Dec 16 15:47:41 GMT 2023 , Edited by admin on Sat Dec 16 15:47:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Enzymatic Inhibition
IC50
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TARGET->WEAK INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Enzymatic Inhibition
IC50
|
||
|
TARGET->WEAK INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
Enzymatic Inhibition
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Enzymatic Inhibition
IC50
|
||
|
TARGET -> INHIBITOR |
Enzymatic Inhibition
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Enzymatic Inhibition
IC50
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
Enzymatic Inhibition
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
blood-to-plasma ratio | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
FED CONDITION |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||